Raju Tom Kalathil, Tadic Srdan, Garrido Pablo, Ochoa-Callejero Laura, Narro-Íñiguez Judit, García-Sanmartín Josune, Martínez Alfredo
Angiogenesis Unit, Oncology Area, Center for Biomedical Research of La Rioja (CIBIR), 26006 Logroño, Spain.
Vaccines (Basel). 2025 May 30;13(6):586. doi: 10.3390/vaccines13060586.
Nucleic acid-based anticancer vaccines are becoming a very active field in the fight against cancer. Here, our goal was to generate an oral DNA vaccine targeting the angiogenic peptide, proadrenomedullin N-terminal 20 peptide (PAMP). An expression plasmid (PcPAMP) was generated by fusing the tetanus toxin epitopes P2 and P30 to the mouse PAMP sequence to counteract self-tolerance, and the empty plasmid was used as a negative control (PcNeg). The plasmids were introduced into bacteria that were then transformed into bacterial ghosts. C57BL/6J mice were orally immunized with the ghosts five times at 2-week intervals. Then, B16-F10 melanoma cells were injected into the tail vein to generate lung metastases. Furthermore, naïve CD4 T cells were exposed to PAMP, and their secretome was analyzed by proximity extension assays. Significant levels of anti-PAMP immunoglobulins were detected in the blood of PcPAMP-vaccinated mice and their levels of spleen CD8 T cells were significantly higher than in those treated with PcNeg, indicating that self-tolerance was effectively broken. Although the number and size of lung metastases was similar between both experimental groups, there was a significant reduction in intratumoral angiogenesis and in cancer cell proliferation index in the PcPAMP group. Furthermore, these animals showed an intense infiltration of lymphocytes, including regulatory T cells, and M2-like macrophages into the metastases, that was not evident in the PcNeg group. In addition, PAMP induced upregulation of IL1β, IL6, IL7, IL12, IL27, TNFα, and FGF21, and downregulation of IL16 in naïve CD4 T cells. Although the vaccine was not effective in reducing tumor growth, new proliferative and immune functions have been described for PAMP. These new functions include induction of melanoma proliferation and modulation of lymphocyte and macrophage tumor infiltration dynamics.
基于核酸的抗癌疫苗正成为抗癌斗争中一个非常活跃的领域。在此,我们的目标是研发一种针对血管生成肽——肾上腺髓质素原N端20肽(PAMP)的口服DNA疫苗。通过将破伤风毒素表位P2和P30与小鼠PAMP序列融合以对抗自身耐受性,构建了一种表达质粒(PcPAMP),空质粒用作阴性对照(PcNeg)。将质粒导入细菌,然后转化为细菌幽灵。C57BL/6J小鼠每隔2周口服细菌幽灵免疫5次。然后,将B16-F10黑色素瘤细胞注入尾静脉以形成肺转移瘤。此外,将未致敏的CD4 T细胞暴露于PAMP,并通过邻近延伸分析对其分泌组进行分析。在接种PcPAMP的小鼠血液中检测到显著水平的抗PAMP免疫球蛋白,其脾脏CD8 T细胞水平显著高于接受PcNeg治疗的小鼠,表明自身耐受性被有效打破。尽管两个实验组之间肺转移瘤的数量和大小相似,但PcPAMP组肿瘤内血管生成和癌细胞增殖指数显著降低。此外,这些动物的转移瘤中出现了包括调节性T细胞和M2样巨噬细胞在内的淋巴细胞强烈浸润,而在PcNeg组中不明显。此外,PAMP诱导未致敏CD4 T细胞中IL1β、IL6、IL7、IL12、IL27、TNFα和FGF21上调,IL16下调。尽管该疫苗在减少肿瘤生长方面无效,但已描述了PAMP的新的增殖和免疫功能。这些新功能包括诱导黑色素瘤增殖以及调节淋巴细胞和巨噬细胞肿瘤浸润动态。